The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 10, 2022

Filed:

Apr. 12, 2016
Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Mark Ayers, Pennington, NJ (US);

Jared Lunceford, Washington, UT (US);

Andrey Loboda, Boston, MA (US);

Michael Nebozhyn, Colmar, PA (US);

Terrill K. McClanahan, Sunnyvale, CA (US);

Heather Hirsch, Brookline, MA (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12Q 1/6886 (2018.01); A61K 39/395 (2006.01); G01N 33/543 (2006.01); G01N 33/566 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 39/39558 (2013.01); G01N 33/543 (2013.01); G01N 33/566 (2013.01); G01N 33/574 (2013.01); G01N 33/68 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.


Find Patent Forward Citations

Loading…